Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  rituximab
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 305 for your search:
Start Over
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810
Mature B-Cell Lymphoma And Leukemia Study III
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: SJBC3, NCT01046825
TREatment of degeNerative and Neoplastic Diseases With Rituximab
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: PRO-1908, PRO1908TREND, NCT01277172
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: ANHL1131, NCI-2012-01963, CDR0000732604, IGR2009/1593, 2010-019224-31, U10CA098543, U10CA180886, COG-ANHL1131, NCT01595048
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory DLBCL Patients Before High-Dose Chemotherapy BEAM With ASCT.
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: FIL_VERAL12, NCT01805557
BNHL-2015 for Children or Adolescents in China
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 16 and under
Sponsor: Other
Protocol IDs: CCCG-BNHL-2015, NCT02405676
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CCBX001-049, NCT00078598
Mega-CHOEP: Conventional Chemo Vs HD Chemo Followed by Auto SCT in Younger Pts With Aggressive Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090
Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: MCL2004-1, NCT00209209
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
LMBA02 Protocol for Patients With a Burkitt Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LMBA02, NCT00180882
Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459685, DSHNHL-2004-2, EU-205110, EUDRACT-2005-00521738, DSHNHL-FLYER-6664, NCT00278421
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: CDR0000459796, DSHNHL-2004-3, EUDRACT-2005-005218-19, EU-205111, NCT00278408
Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: GRAALL 2005, NCT00327678
Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Treating Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: CDR0000589684, CHRUT-LLC-2007-SA, CHRUT-PHRN05-CD, INCA-RECF0497, EUDRACT-2007-001015-28, LLC 2007 SA, NCT00645606
Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: EUDRACT: 2005-00700-14, NCT00355199
Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 16 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: ASI-HDIII 0109, NCT00816959
Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: NHL 7-2008, NCT00877214
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 113676, NCT01200589
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: ISRCTN99217456, 2008-004759-31, NCT01303887
Start Over